You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The researchers are developing an automated machine-learning approach to analyze the expression of protein markers associated with cervical cancer.
Yale researchers said that they anticipate their RNA extraction-free saliva assay will make testing more scalable, affordable, and available to the public.
Chembio suggested a device modification could improve performance, following an analysis of troubling NCI data. The FDA didn't agree.
A research team said the study provides some evidence that there is potential for saliva testing in broad surveillance of past exposure to SARS-CoV-2.
In a proof-of-concept study, the group has demonstrated its platform could detect a biomarker of breast tumor metastasis and other disease biomarkers.
Clinicians at Addenbrooke's Hospital in the UK are seeing reduced time to result and additional clinical benefits from using the DRW SAMBA II SARS-CoV-2 assay.
The developer said that use of gold nanoparticles enables use at the point of care and inexpensive signal amplification that eliminates traditional equipment.
The FDA has added an at-home self-collection template to its SARS-CoV-2 EUA guidance as more firms seek to develop sampling kits for use in homes.
The startup is developing a qPCR-based profiling method that could provide results within hours to clinicians treating their cancer patients with immune checkpoint inhibitors.
The group believes its assay, which detects HPV-16 DNA, could be deployed as a screening test in the way that HPV is currently screened to prevent cervical cancer.